z-logo
Premium
Activation of NRF2 Signaling in HEK293 Cells by a First‐in‐Class Direct KEAP1‐NRF2 Inhibitor
Author(s) -
Wen Xia,
Thorne Gabriell,
Hu Longqin,
Joy Melanie S.,
Aleksunes Lauren M.
Publication year - 2015
Publication title -
journal of biochemical and molecular toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.526
H-Index - 58
eISSN - 1099-0461
pISSN - 1095-6670
DOI - 10.1002/jbt.21693
Subject(s) - keap1 , hek 293 cells , sulforaphane , transcription factor , chemistry , microbiology and biotechnology , activator (genetics) , heme , cytoprotection , biology , biochemistry , gene , apoptosis , enzyme
Under basal conditions, the antioxidant transcription factor nuclear factor (erythroid‐derived 2)‐like 2 (NRF2) is bound to the Kelch‐like ECH‐associated protein 1 (KEAP1) protein and targeted for proteasomal degradation in the cytoplasm. In response to cellular injury or chemical treatment, NRF2 dissociates from KEAP1 and activates the transcription of protective genes and defends against injury. LH601A is a first‐in‐class direct inhibitor of the KEAP1‐NRF2 protein–protein interaction. The purpose of this study was to determine whether LH601A activates NRF2 signaling in human kidney cells. Human embryonic kidney 293 (HEK293) cells were treated with LH601A or the indirect NRF2 activator, sulforaphane (SFN) for 6 or 16 h. SFN and LH601A upregulated NRF2 target genes heme oxygenase‐1 (HO‐1) (two‐ to sevenfold), thioredoxin 1 (TRX1) (twofold) and NAD(P)H quinone oxidoreductase 1 (NQO1) mRNAs (twofold). Both compounds also elevated HO‐1 and TRX1 protein expression. Since NRF2 activation can protect tissues from injury, LH601A, a direct inhibitor of the KEAP1‐NRF2 interaction may be used to defend against kidney injury and/or diseases.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here